... company's stock valued at $5,712,000 after acquiring an additional 170,126 shares in the last quarter. Finally, Ardsley Advisory Partners raised its position in shares of CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory ...
http://ift.tt/2AgOdqL
No comments:
Post a Comment